Testing FD-001 for blood cancers that returned or didn't respond
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a blood cancer (like AML, MDS, myeloma, lymphoma, or some others) that standard treatments didn't help or you couldn't tolerate.
- You have at least one sign of active disease that can be measured, like abnormal cells in bone marrow or blood, or a visible tumor on a scan.
- You have recovered enough from side effects of prior treatments (except hair loss) and your organ function is good enough based on blood tests.
- You haven't had certain cancer treatments or vaccines in the past 2 to 4 weeks before starting the study drug.
- You do not have other active cancers or conditions like central nervous system involvement, chronic myeloid leukemia with BCR/ABL gene, or severe allergies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
This early-stage study tests an experimental drug called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug targets a protein called CD38 on leukemia cells, and the goal is to see if it is safe and helpful.
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
Hear when a new NHL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.